OncRef

Clinical Trial: NCT04148911

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2025-12-26

Study Overview

Brief Summary

Study MO39874 is an open-label, Phase IIIb, single arm, global study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

Official Title

An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Conditions

Triple-Negative Breast Cancer

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Nab-Paclitaxel

Other Study ID Numbers

  • MO39874
  • 2019-002488-91
  • 2019

Start Date (Actual)

2019-12-10

Primary Completion Date (Actual)

2024-12-15

Study Completion Date (Actual)

2024-12-15

Enrollment (Actual)

184

Study Type

Interventional

Phase

Phase 3